Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03853109 · ClinicalTrials.gov registry record · Phase 1
AMG 404 in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 171
- Enrollment target
NCT03853109 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 171 participants.
The verdict
NCT03853109, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 171 participants
- Enrollment target
Study Summary
To evaluate the safety and tolerability of AMG 404, a monoclonal antibody that binds to PD-1 and inhibits its engagement with ligands, in patients with advanced solid tumors.
Interventions
- DRUG AMG 404
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 171 participants |
| Start Date | 2019-03-05 |
| Est. Completion | 2023-11-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03853109
The ClinicalTrials.gov registry entry for NCT03853109 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 171 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AMG 404 is the first listed.
NCT03853109 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03853109 about?
NCT03853109 is a clinical study titled "AMG 404 in Patients With Advanced Solid Tumors". To evaluate the safety and tolerability of AMG 404, a monoclonal antibody that binds to PD-1 and inhibits its engagement with ligands, in patients with advanced solid tumors.
What is the current status of trial NCT03853109?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 171 participants. The study started on 2019-03-05. Estimated completion is 2023-11-02.
What interventions are being tested in trial NCT03853109?
The interventions under investigation include: AMG 404 (DRUG).
Who is sponsoring clinical trial NCT03853109?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.